Citi views the FDA’s complete response letter sent to Biogen (BIIB) regarding its supplemental new drug application for the higher dosing regimen of Spinraza for spinal muscular atrophy as a “manageable road bump.” Citi expects ultimate approval and believes the letter should not take much time to resolve. It keeps a Neutral rating on Biogen with a $135 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Growth Outlook: Navigating FDA Delays and Pipeline Maturation
- Biogen’s Hold Rating Maintained Amid Uncertainty Over FDA’s CRL on Nusinersen
- Biogen’s Spinraza High-Dose Application Faces Technical Hurdle, Buy Rating Maintained
- FDA requests update to technical information of Biogen nusinersen sNDA
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!